Form 4: Scholar Rock Holding Corp. Chief Medical Officer Executes Stock Transactions Under 10b5-1 Plan

Scholar Rock's Chief Medical Officer, Jing L. Marantz, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Summary

• Jing L. Marantz, Chief Medical Officer of Scholar Rock Holding Corp., engaged in several transactions involving the company's common stock.
• These transactions included the exercise of stock options and the subsequent sale of shares.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 19, 2024.
• On November 22, 2024, 2,145 shares were acquired through option exercise at $8.59 per share and then sold at a weighted average price of $30.0102.
• On November 25, 2024, 6,375 shares were acquired through option exercise at $8.59 per share and then sold in multiple transactions at weighted average prices ranging from $38.041 to $40.72.
• Following these transactions, Marantz directly owns 72,855 shares of common stock and 130,000 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan. There is no indication of positive or negative sentiment, it is a neutral event.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.
• The exercise of stock options indicates that the executive believes in the long-term value of the company.

Negatives

• The sale of shares by the Chief Medical Officer could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to insider selling, even if it is part of a pre-planned trading plan.
• Fluctuations in the stock price could impact the value of the remaining stock options held by the executive.

Industry Context

This type of filing is standard for publicly traded companies and reflects the trading activity of company insiders. It is common for executives to use 10b5-1 plans to manage their stock holdings.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Scholar Rock.
• Similar filings are regularly seen from executives at companies such as Biogen (BIIB) and Vertex Pharmaceuticals (VRTX), where stock options are a significant part of compensation.
• The vesting schedule of the options, with a four-year vesting period and quarterly installments, is also typical for executive compensation packages in the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.
• The sales could slightly increase the float of the stock.

Key Dates

Keywords

insider trading, stock options, Rule 10b5-1, stock sales, common stock, executive compensation, SRRK, Scholar Rock